Drugs / 89ZR-DF-IAB2M
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01923727 | Aug 2013 → May 2016 | metastatic prostate carcinoma | ImaginAb, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03675451 | Feb 2017 → Jun 2018 | prostate cancer | Weill Medical College of Cornell University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [89Zr]Df-IAB2M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01923727 ↗ |
| Modality | Protein / enzyme biologic | “an approximately 80 kDA molecular weight antibody fragment (a "Minibody")” NCT01923727 ↗ |
| Route | Intravenous | “A single intravenous infusion” NCT01923727 ↗ |